CD19 and acquired idiopathic inflammatory myopathy: Recently, researchers evaluated the safety and efficacy of CD19 CAR-T-cell therapy in 15 patients with severe autoimmune diseases, including SLE, idiopathic inflammatory myositis, and systemic sclerosis (MS).